Solorank.ai
Login

Cached score snapshot

US.GILD · Gilead Sciences

110分制 56.1/110；5D動能v2 9/50；排序分 65.1/160

Back to ranking Open volume snapshot
Ranking score 65.1/160
Main score 56.1/110
5D momentum v2 9/50
Rank #237
Setup grade F 32.2

Score breakdown

觀望

Medium twelvedata

Score and price trend

F 32.2 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 07-20 09-10 10-20 11-05 11-23 $124.31$148.21$172.11 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.616 · anchors 120 +1.36% -1.01% / +2.91% 65% 0% Actual +4.61% · vs median +3.25% · inside 25-75 band
30D observation +2.72% -5.32% / +6.68% 52.5% 27.5% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +0.36% -1.81% / +2.46% 53.8% 3.8% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-07-20 → 2026-11-23 · 148 archived points · 2 Improving turn signal · 7 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 65.1
Display grade 觀望
Model version cursor_18_27_news_v2_160
Main score 56.1/110 (觀望)
5D momentum v2 9/50 (弱)
Score with momentum v2 65.1/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60
ma20 148.9695
ma50 145.116
close 150.43
prevClose 151.17
avgVolume20 5844674
volumeRatio 0.9
changePercent -0.49

Metrics snapshot

close 150.43
volume 5231071
changePercent -0.49

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 56.1/110
Main rating 觀望
5D momentum v2 9/50
Score with momentum v2 65.1/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 2.5/5 · 較差
Dimension score 2.5/5
Dimension grade 較差

Sub-items

pbPoints 0.2
pePoints 0
epsPoints 0.6
roePoints 0
debtPoints 0.3
marginPoints 0
turnoverUsdM 786.91
volumePoints 0.5
revenuePoints 0
dividendPoints 0.4
marketCapPoints 0.5

資金流 — 8.4/20 · 較差
Dimension score 8.4/20
Dimension grade 較差

Sub-items

cmfPoints 1.6
mfiPoints 1.6
obvPoints 0.8
vwapPoints 2.4

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.GILD
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 12.6/15 · 優秀
Dimension score 12.6/15
Dimension grade 優秀

Sub-items

vix

score 2.4

details

source twelvedata+fred
vixClose 14.84

trend

score 4

details

qqq

ma20 739.3845
ma50 725.6844
name QQQ
close 746.04
points 2

spy

ma20 768.838
ma50 768.1958
name SPY
close 778.1
points 2
source twelvedata+fred
atrPct 2.2436
atrPoints 3
cciPoints 3.2
vixPoints 2.4
marketTrendPoints 4

催化劑 — 2/20 · 較差
Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 8
catalystCount 0
catalystPoints 2

風險管理 — 7.4/10 · 良好
Dimension score 7.4/10
Dimension grade 良好

Sub-items

position

score 1.6

details

atrPct 2.2436
turnoverUsdM 786.91
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.GILD
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 143.68

strength_details

ma_score 1.5
atr_score 2
rsi_score 1
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1.1
stop_loss_percent 4.5
take_profit_price 157.9515
target_multiplier 1.6
technical_strength 1.38
take_profit_percent 5
positionPoints 1.6
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 4.4871
diversificationPoints 2

技術信號 — 19.2/30 · 一般
Dimension score 19.2/30
Dimension grade 一般

Sub-items

bbPoints 3
adxPoints 3
sarPoints 2.4
vcpPoints 1
macdPoints 2.4

vcpPayload

vcp_pass false
vcp_score 1
vcp_reason 跌縮量(近10日5日)；站上MA50；Ready=N；Confirm=N

vcp_metrics

up_days 3
vol_ref 5615950
down_days 6
vcp_ready false
above_ma50 true
avg_vol_10 5048770
avg_vol_20 5829115
avg_vol_30 5615950
range_pct_10 0.0674
range_pct_20 0.0771
range_pct_30 0.0771
up_expand_ok false
lookback_used 59
near_20d_high true
contraction_ok false
down_shrink_ok true
up_expand_days 1
breakout_20d_ok false
vol_ratio_10_30 0.899
dist_to_20d_high 0.0244
down_shrink_days 5
breakout_level_20d 154.2
vcp_breakout_confirm false
contraction_ratio_10_30 0.8741
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction false
kdjAdxPoints 0.8
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0.8
shortMacdPoints 0.4
volConfirmPoints 0.6
volumePointsTechnical 0.8

情緒分析 — 4/10 · 較差
Dimension score 4/10
Dimension grade 較差

Sub-items

sentiment

score 4

details

source finnhub_news_keyword_model
articleCount 8
negativeHits 0
positiveHits 2
sentimentScoreRaw 0.6

sentimentData

raw {"id":142820058,"url":"https://finnhub.io/api/news?id=9387852c7120fcdd29adfdb910505d1715b53c6deb397f2a103e66cc75fb8070","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences, Inc. (NASDAQ:GILD) shares are up more than 24% this year, ahead of the S&P 500’s 14%. Gilead makes HIV, liver disease and cancer drugs. The stock is part of our coverage of the 8 best-performing stock picks by Claude AI in 2026. Why Gilead Stock Is Up Gilead Q2 sales rose 10% year […]","category":"company","datetime":1791812886,"headline":"Can Gilead (GILD) Stock Continue Rising in 2027?"}, {"id":142800040,"url":"https://finnhub.io/api/news?id=c8aa46e1dffb5aa548e1d5eb4f7927364c339382e45bda6fd9b4941975c85a4f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences stock has delivered a strong multi year run, which puts a spotlight on whether the current share price still lines up with the company’s sales base. With fresh headlines on earnings, partnerships and pipeline progress, the real question for investors is how much of Gilead’s revenue story is already reflected in today’s valuation. Over the past 5 years, Gilead Sciences has returned 167.1%. Anyone looking at the stock now is asking how that kind of gain squares with its sales...","category":"company","datetime":1791699157,"headline":"Is Gilead Sciences (GILD) Undervalued After Strong Q2 Sales?"}, {"id":142767972,"url":"https://finnhub.io/api/news?id=af60f572cf52793220433c93cd385c0045a9e6799c65229ac00d8dfd2ffe59ea","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences (GILD) closed the most recent trading day at $151.17, moving +2.77% from the previous trading session.","category":"company","datetime":1791579604,"headline":"Gilead Sciences (GILD) Laps the Stock Market: Here's Why"}, {"id":142732213,"url":"https://finnhub.io/api/news?id=3a09402950476f7fcd62242a96163f1a6fd9721187ff48031e02e64cda88ce45","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers.","category":"company","datetime":1791483849,"headline":"Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)"}, {"id":142633635,"url":"https://finnhub.io/api/news?id=1ee8e3d0524fdbb67e1b948471d2d665c7caaa16cfef8d1ed997e51aab395757","image":"https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp","source":"ChartMill","related":"GILD","summary":"Gilead Sciences (GILD) passes a high-quality dividend screen with a 3.98% yield, strong profitability, cheap valuation, and key risks to watch.","category":"company","datetime":1791199251,"headline":"Gilead Sciences (NASDAQ:GILD) Offers Dividend Investors Quality Income and Valuation Support"}, {"id":142593657,"url":"https://finnhub.io/api/news?id=5643f6193002955ede3dce056dee6d1f7e7ad82b31f17d9f60e3e061f62c74c3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences (GILD) closed the most recent trading day at $144.74, moving 1.87% from the previous trading session.","category":"company","datetime":1790974205,"headline":"Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know"}, {"id":142583871,"url":"https://finnhub.io/api/news?id=d2a40d543e277ab2d63941b69cc09eb6a30b1761af305596648930b9bf5b9b47","image":"https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp","source":"ChartMill","related":"GILD","summary":"Gilead Sciences (GILD) earns a 10/10 Technical Rating and 8/10 Setup Quality on ChartMill's breakout screen. See entry, stop, and risk levels.","category":"company","datetime":1790935861,"headline":"Gilead Sciences (NASDAQ:GILD) Combines Top Technical Strength With a High-Quality Breakout Setup"}, {"id":142557827,"url":"https://finnhub.io/api/news?id=000dade194eb1687191ad8725a86ca0b193f09fd993e8590b624ef11c675f376","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.","category":"company","datetime":1790856005,"headline":"Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It"}
raw_source {"id":142824587,"url":"https://finnhub.io/api/news?id=4ada72fac9123a59143a240d812a2ab69d3c89f7ae6796e066c81830e7e4ce67","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobrutideg combination strategy with initiation of recruiting for the Phase 1b/2 NX-5948-203 study Earned $27M from Gilead, Pfizer and Sanofi collaborations, including a $10M milestone from Sanofi for first patient dosed in the STAT6 degrader Phase 1 trial Advanced NX-1607 into Phase 1b expansion cohorts in MSS CRC, NSCLC, CRPC and melanoma with","category":"company","datetime":1791835500,"headline":"Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update"}, {"id":142821709,"url":"https://finnhub.io/api/news?id=276bb6be8569f3edf6bab8119b219d4362fa18e04700f2f3471617ab034cd050","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences' (GILD) HIV prevention drug Yeztugo's long-term growth outlook is supported by a phy","category":"company","datetime":1791817629,"headline":"Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says"}, {"id":142820058,"url":"https://finnhub.io/api/news?id=9387852c7120fcdd29adfdb910505d1715b53c6deb397f2a103e66cc75fb8070","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences, Inc. (NASDAQ:GILD) shares are up more than 24% this year, ahead of the S&P 500’s 14%. Gilead makes HIV, liver disease and cancer drugs. The stock is part of our coverage of the 8 best-performing stock picks by Claude AI in 2026. Why Gilead Stock Is Up Gilead Q2 sales rose 10% year […]","category":"company","datetime":1791812886,"headline":"Can Gilead (GILD) Stock Continue Rising in 2027?"}, {"id":142805485,"url":"https://finnhub.io/api/news?id=018c09de44fa21b891968fbffafbc07e0dd112a55fd397ec10cf1709e1997a4a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences, Inc. (NASDAQ:GILD) has had a considerably better year than the broader market. The stock has surged by over 24% since the start of the year, compared with a 14% return for the S&P 500. The rally has changed the valuation equation. Yahoo Finance recently put Gilead’s normalized forward P/E at approximately 15.5 times. […]","category":"company","datetime":1791724616,"headline":"Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive?"}, {"id":142800040,"url":"https://finnhub.io/api/news?id=c8aa46e1dffb5aa548e1d5eb4f7927364c339382e45bda6fd9b4941975c85a4f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences stock has delivered a strong multi year run, which puts a spotlight on whether the current share price still lines up with the company’s sales base. With fresh headlines on earnings, partnerships and pipeline progress, the real question for investors is how much of Gilead’s revenue story is already reflected in today’s valuation. Over the past 5 years, Gilead Sciences has returned 167.1%. Anyone looking at the stock now is asking how that kind of gain squares with its sales...","category":"company","datetime":1791699157,"headline":"Is Gilead Sciences (GILD) Undervalued After Strong Q2 Sales?"}, {"id":142772223,"url":"https://finnhub.io/api/news?id=d7341b07311e0a7aadb936df0d126442fa321eed83f51e517867f131ac1fb044","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences (GILD) generated free cash flow equal to 7.1% of its market value over the last twelve months. The median S&P 500 company yielded just 4.5% over the same period. A yield that high means one of two things: the business is either trading at a steep discount, or the market expects it to shrink. So why are investors paying so little for Gilead's cash.","category":"company","datetime":1791593224,"headline":"Why Is Everyone Ignoring Gilead Stock's High Cash Yield?"}, {"id":142767972,"url":"https://finnhub.io/api/news?id=af60f572cf52793220433c93cd385c0045a9e6799c65229ac00d8dfd2ffe59ea","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences (GILD) closed the most recent trading day at $151.17, moving +2.77% from the previous trading session.","category":"company","datetime":1791579604,"headline":"Gilead Sciences (GILD) Laps the Stock Market: Here's Why"}, {"id":142732213,"url":"https://finnhub.io/api/news?id=3a09402950476f7fcd62242a96163f1a6fd9721187ff48031e02e64cda88ce45","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers.","category":"company","datetime":1791483849,"headline":"Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)"}, {"id":142726119,"url":"https://finnhub.io/api/news?id=8d63381bbde91898ccdd27d5aa01cfb39426588cb7095723b0067b83509ee531","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Cognizant Technology Solutions (NasdaqGS: CTSH) announced multi-year AI-focused partnerships with Gilead Sciences and SITA. The Gilead agreement targets AI-enabled DevOps and finance transformation programs using Cognizant's cloud and automation capabilities. The SITA collaboration focuses on applying Cognizant's AI tools across global air transport technology systems and related services. Cognizant also introduced Cognizant Activate, a program aimed at speeding AI adoption for emerging...","category":"company","datetime":1791458126,"headline":"What Is Cognizant Technology Solutions (CTSH) Signaling With Its Latest AI Push?"}, {"id":142728774,"url":"https://finnhub.io/api/news?id=0e8e95897c3fe2fcf0ba7270fedde6c15cf641d02a653be38505f5776ac2c319","image":"","source":"Benzinga","related":"GILD","summary":"RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $123 to $126.","category":"company","datetime":1791453693,"headline":"RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $126"}, {"id":142728775,"url":"https://finnhub.io/api/news?id=66241126a5570aa7f36882c20ca675816372ae8e0a1e173404131fdca173b161","image":"","source":"Benzinga","related":"GILD","summary":"Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.","category":"company","datetime":1791441772,"headline":"Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target"}, {"id":142701393,"url":"https://finnhub.io/api/news?id=da94b08ce470a3378e56e75d8c59b4f34f9e709c3a28f65cbc1d5af53a06c7b3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Nurix Therapeutics, Inc. recently announced that it has extended by two years the research term for an undisclosed oncology program under its ongoing collaboration with Gilead Sciences, originally established in 2019 to develop E3 ligase–based protein degradation therapies. This extension underscores continued progress in a partnership that could earn Nurix up to approximately US$1.30 billion in potential payments, plus tiered royalties on any future commercial products, with options for...","category":"company","datetime":1791415027,"headline":"Is Extending the Gilead E3 Ligase Collaboration Altering The Investment Case For Nurix Therapeutics (NRIX)?"}, {"id":142701310,"url":"https://finnhub.io/api/news?id=be0a7e3fa760ed5f0a5c52227739c617a8ce6b41a96fbf2c446e8d620797eaa5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Exelixis (EXEL) stock has returned 46% over the past twelve months, compared with 17.8% for the S&P 500. The company has aggressively repurchased its own stock, reducing its total share count by 21% over the last three years. Because fewer shares remain in circulation, each one lays claim to a larger slice of the profit. So how much is that buyback adding to each Exelixis share you own.","category":"company","datetime":1791414880,"headline":"Is Exelixis Stock Engineered To Make You Money?"}, {"id":142700439,"url":"https://finnhub.io/api/news?id=da80826b64e80f1594dae15b7d87a27233f733bf721bc6594d3507759e01fcbf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Abbott Laboratories (NYSE:ABT) is a business that is not showcasing any rapid growth trends. However, what makes it an attractive investment prospect is the company’s consistent track record of incremental dividends, with 411 consecutive quarterly payouts since 1924. Along with the company’s underlying business mix, it makes Abbott a suitable investment for dividend hunters. The […]","category":"company","datetime":1791406181,"headline":"Is Abbott Laboratories (ABT) a Dividend Bargain After Its 2026 Selloff?"}, {"id":142694679,"url":"https://finnhub.io/api/news?id=dfa716cf5868aea56979acaaf21f82e903edf0b1c71862029996a12e650ff5cc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"The Dow Jones index drops 450 points Wednesday as Treasury yields jump. The Fed minutes are due later in the day.","category":"company","datetime":1791383028,"headline":"Stock Market Today: Dow Tumbles 450 Points As Yields Jump; Fed Minutes On Deck (Live Coverage)"}, {"id":142728776,"url":"https://finnhub.io/api/news?id=dbd10737ccf082ae93a8fe65116ea381d0c97502c38963e0c51442d6e7122140","image":"","source":"Benzinga","related":"GILD","summary":"Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $150 to $158.","category":"company","datetime":1791377252,"headline":"Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158"}, {"id":142728777,"url":"https://finnhub.io/api/news?id=0624c05c74a0897e9c717dd9efeef8b3ef8715fe951533f7dce139900d0d6909","image":"","source":"Benzinga","related":"GILD","summary":"JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $160 to $170.","category":"company","datetime":1791376523,"headline":"JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170"}, {"id":142696751,"url":"https://finnhub.io/api/news?id=8308e808fdc23788f000e70153d42c9acc20ae41a151b1ef8a6ad65aa86d7bfe","image":"","source":"Benzinga","related":"GILD","summary":"Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $165 to $163.","category":"company","datetime":1791369244,"headline":"Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163"}, {"id":142688722,"url":"https://finnhub.io/api/news?id=4608d9e544ba0975401ceb401b4517d7267b0fe2a1145ef60aa3e03161a0b159","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"The arrangement will see Cognizant combine its life sciences knowledge with technical services to aid Gilead's processes.","category":"company","datetime":1791361316,"headline":"Gilead Sciences signs five-year DevOps agreement with Cognizant"}, {"id":142663035,"url":"https://finnhub.io/api/news?id=0d8e033e32e58d924869cfeb3451cdfdc3a2e75cc7006065c6c6eb170d96ead5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapiesTEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of biopharmaceutical executive Laura Hamill to its Board of Directors, effective December 1, 2026. Ms. Hamill brings more than 35 years of global commercial, market","category":"company","datetime":1791288000,"headline":"Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise"}, {"id":142664221,"url":"https://finnhub.io/api/news?id=706faaac00d6e5ed27a643901c5203ca14fd47a9c44c4692b3c93a9cc1da79ed","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2236050381/image_2236050381.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"GILD","summary":"Gilead Sciences remains a Hold: HIV drives Q2 growth, but oncology/CAR‑T lags and costly M&A strains FCF. Click to read this latest analysis of GILD stock.","category":"company","datetime":1791282950,"headline":"Gilead: Buying Growth Isn't Free, And The Discounted Cash Flow Model Knows It"}, {"id":142639194,"url":"https://finnhub.io/api/news?id=7933b7eae46aa038abbaf842273cb447cd5fdc97b16d1c6884ce82e32a3ccf64","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Compugen (NASDAQ:CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, research during a company update event. President and Chief Executive Officer Er","category":"company","datetime":1791234127,"headline":"Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets"}, {"id":142638690,"url":"https://finnhub.io/api/news?id=770bacb7f8482a023eeb2dc94987553cc4ae2ef4df216448c7835c9cf3b21dcf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cara Bauer, Ph.D., has been named Executive Vice President, Chief People Officer. Ms. Bauer will assume responsibility for the company's Human Resources organization, effective Oct. 5, succeeding Amy Wireman, who is retiring.","category":"company","datetime":1791230700,"headline":"BioMarin Appoints Cara Bauer as Chief People Officer"}, {"id":142666467,"url":"https://finnhub.io/api/news?id=d4ac3a4a79016711df083f84db8896c82df32e71f0e91404648636116ee3dc93","image":"https://image.cnbcfm.com/api/v1/image/108317496-1780677508197-gettyimages-2279271508-US_STOCKS.jpeg?v=1780677968&w=1920&h=1080","source":"CNBC","related":"GILD","summary":"Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.","category":"company","datetime":1791215070,"headline":"AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment "}, {"id":142633635,"url":"https://finnhub.io/api/news?id=1ee8e3d0524fdbb67e1b948471d2d665c7caaa16cfef8d1ed997e51aab395757","image":"https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp","source":"ChartMill","related":"GILD","summary":"Gilead Sciences (GILD) passes a high-quality dividend screen with a 3.98% yield, strong profitability, cheap valuation, and key risks to watch.","category":"company","datetime":1791199251,"headline":"Gilead Sciences (NASDAQ:GILD) Offers Dividend Investors Quality Income and Valuation Support"}, {"id":142633238,"url":"https://finnhub.io/api/news?id=136a49bfb05df5a9089c4ef5e21f5cfa9a33f83fe036d3e05b121b5dc1d46c75","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Two-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Nurix and Gilead Sciences have agreed to extend th","category":"company","datetime":1791198000,"headline":"Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences"}, {"id":142634785,"url":"https://finnhub.io/api/news?id=b09602f8cd28237e64b2feb5ab368e47947df589ef7f11b385fd04a49f5fb127","image":"","source":"Benzinga","related":"GILD","summary":"Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Nurix and","category":"company","datetime":1791184220,"headline":"Nurix Gets $10M As Gilead Extends Drug Discovery Deal"}, {"id":142593657,"url":"https://finnhub.io/api/news?id=5643f6193002955ede3dce056dee6d1f7e7ad82b31f17d9f60e3e061f62c74c3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences (GILD) closed the most recent trading day at $144.74, moving 1.87% from the previous trading session.","category":"company","datetime":1790974205,"headline":"Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know"}, {"id":142591878,"url":"https://finnhub.io/api/news?id=ab2ab560f4925378beb465ae0245e168c9c54c5752738e6f441da4f852ff4daa","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Legend Biotech's (LEGN) multiple myeloma therapy Carvykti is facing growing competitive pressure as","category":"company","datetime":1790960724,"headline":"Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says"}, {"id":142583871,"url":"https://finnhub.io/api/news?id=d2a40d543e277ab2d63941b69cc09eb6a30b1761af305596648930b9bf5b9b47","image":"https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp","source":"ChartMill","related":"GILD","summary":"Gilead Sciences (GILD) earns a 10/10 Technical Rating and 8/10 Setup Quality on ChartMill's breakout screen. See entry, stop, and risk levels.","category":"company","datetime":1790935861,"headline":"Gilead Sciences (NASDAQ:GILD) Combines Top Technical Strength With a High-Quality Breakout Setup"}, {"id":142571013,"url":"https://finnhub.io/api/news?id=6758043f688f5542b6b2266dafaa9d9f866fb6e649d41d2479708fe276cddfa4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead shares are up 35% since Barron’s highlighted them, but our catalysts have yet to fully play out.","category":"company","datetime":1790907900,"headline":"More Upside Awaits for Gilead Sciences Stock. Stay Invested."}, {"id":142557827,"url":"https://finnhub.io/api/news?id=000dade194eb1687191ad8725a86ca0b193f09fd993e8590b624ef11c675f376","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.","category":"company","datetime":1790856005,"headline":"Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It"}, {"id":142524905,"url":"https://finnhub.io/api/news?id=6dc0243d4d8773f3b636e269fc5c987d4f33de8084d0d43758910c07cba58ac4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"In the latest trading session, Gilead Sciences (GILD) closed at $149.45, marking a -1.21% move from the previous day.","category":"company","datetime":1790802004,"headline":"Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors"}, {"id":142512602,"url":"https://finnhub.io/api/news?id=37a1437e25f832cb49b993def235bdaf39695b5184d86e5c9fd31392f0d35df6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding clinical trials, and increased investment, while high costs and adverse effects remain barriers. Yescarta led the product market in 2025, hospitals were the largest end-user segment, and Asia Pacific is forecast to record the fastest growth through 2031.Dublin, Sept. 30, 2026","category":"company","datetime":1790758020,"headline":"CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J"}, {"id":142519387,"url":"https://finnhub.io/api/news?id=687625e0f538d148fbd8ba992f2b1d8d80bf64384c725456d7bf8e3272166362","image":"https://cdn.benzinga.com/files/images/story/2026/09/30/Former-President-Bill-Clinton-at-an-even.jpg?width=2048&height=1536","source":"Benzinga","related":"GILD","summary":"Clinton warns abrupt HIV funding shifts could disrupt treatment and prevention, saying “a deadline isn’t a transition plan” and lives could be at risk.","category":"company","datetime":1790745982,"headline":"Bill Clinton Sounds Alarm on HIV Funding: ‘Cheaper Medicines Mean Nothing If They Never Reach People’"}, {"id":142495911,"url":"https://finnhub.io/api/news?id=6533df3c2a8cdaff76083d569ab9807c7a728ed4612ae794478ac3f4b06bbef4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"BOSTON, September 29, 2026--Sware, Inc., the company behind the Res_Q, the AI-powered validation platform, and provider of GxP compliance solutions, today announced the appointment of Mark Hill to its Board of Directors.","category":"company","datetime":1790686800,"headline":"Former Gilead CIO and CSL Chief Digital & Information Officer Mark Hill Joins Sware Board of Directors"}, {"id":142489003,"url":"https://finnhub.io/api/news?id=5a4e02a411bac236db5d78e54ee8716b187340eb56fb0a2c23a7c7fcfd2c7fc3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"AI, computational design and high-throughput screening are accelerating discovery, while targeted therapies, outsourcing and Asia-Pacific expansion create opportunities.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- \"Small Molecule Drug Discovery - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global small molecule drug discovery market was valued at US$61.5 billion in 2024 and is projected to reach US$100 billion by 2030, expanding at a compound annual g","category":"company","datetime":1790673720,"headline":"Small Molecule Drug Discovery - Global Strategic Business Report Forecasts Growth from $61.5B (2024) to $100B by 2030, Profiling AstraZeneca, Gilead Sciences, Merck & Pfizer"}, {"id":142479811,"url":"https://finnhub.io/api/news?id=0714d67165220c8b178a13db884659ebba3b5e3fa2614bf91c2118312f3effd4","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2244980373/image_2244980373.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"GILD","summary":"Pfizer has a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. Find out why PFE stock is a Buy.","category":"company","datetime":1790649185,"headline":"Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough"}, {"id":142472052,"url":"https://finnhub.io/api/news?id=488e40a32cb2988bc5000c8d285752cf0d607b375cc72d91f99ffe688692a18c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"On September 16, Gilead Sciences, Inc. (NASDAQ:GILD) expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to cover an investigational once-yearly formulation for HIV pre-exposure prophylaxis (PrEP). Covering 120 high-incidence, lower-income countries, the expanded framework aims to accelerate manufacturing readiness and technology transfer during the ongoing Phase 3 PURPOSE 365 study. Following […]","category":"company","datetime":1790639523,"headline":"Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase?"}, {"id":142470291,"url":"https://finnhub.io/api/news?id=c1a29e6923dd60319cf3d8cf5214d780ef3c4e0ca7128a19e93e684c9184dcf8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"At first glance, Gilead Sciences, Inc. (NASDAQ:GILD) and Intuitive Surgical, Inc. (NASDAQ:ISRG) don’t make for the most obvious comparison. One sells medicines led by a massive HIV franchise, while the other has built its business around robotic surgery. Yet both have given investors a similar reason to pay attention this year, which is that growth […]","category":"company","datetime":1790623645,"headline":"Gilead vs. Intuitive Surgical: Which Healthcare Stock Offers the Better Risk-Adjusted Upside?"}, {"id":142470289,"url":"https://finnhub.io/api/news?id=a7083a919d52bb2392d245f7cc8b44ce2561bdc6e2c5dccbf125b8b71a586848","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences, Inc. (NASDAQ:GILD) and Danaher Corporation (NYSE:DHR) are both showing signs of stronger growth, but they are getting there in very different ways. Gilead already has momentum, which is supported by its HIV business that is expanding at a double-digit rate, with newer products contributing more and resulting in management raising its sales outlook. […]","category":"company","datetime":1790621106,"headline":"Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?"}, {"id":142470257,"url":"https://finnhub.io/api/news?id=cf5570cdb7032e4ea4fe0efe4335287bed3d60c8fc46c4df6b5504877c967f47","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences, Inc. (NASDAQ:GILD) and Thermo Fisher Scientific Inc. (NYSE:TMO) are benefiting from two very different sources of growth. Gilead’s momentum is being driven primarily by its HIV portfolio, where established medicines and newer products are expanding rapidly. Thermo Fisher, meanwhile, is beginning to benefit from strengthening customer activity across the life-sciences markets it serves […]","category":"company","datetime":1790618905,"headline":"Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?"}, {"id":142466403,"url":"https://finnhub.io/api/news?id=c672a63edc3419bbb2970893f2d87cb95bad7b6ae639d9cb2283dc5a7df67aa9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences (GILD) has put fresh numbers on the table, raising its 2026 sales outlook and lifting its quarterly dividend by 3.8%, a combination that tends to grab investor attention. That guidance change is landing in a stock that already has momentum behind it, with a 90 day share price return of 19.46% and a year to date move of 24.12%. Over the longer haul, Gilead Sciences has delivered a 37.33% 1 year total shareholder return and triple digit total shareholder returns over 3 and 5...","category":"company","datetime":1790601094,"headline":"Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend?"}, {"id":142450685,"url":"https://finnhub.io/api/news?id=c271b58558e32907ae90c0fb83fb80fa9e21bae8fe51ff068d9475cac631a4e5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences, Inc. (NASDAQ:GILD) and Medtronic plc (NYSE:MDT) both combine growing healthcare businesses with regular cash returns to shareholders, but the sources of that growth look very different. Gilead is being propelled by its dominant HIV portfolio, where several products are expanding rapidly. On the other hand, Medtronic’s growth is spread across a much broader […]","category":"company","datetime":1790551205,"headline":"Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income?"}, {"id":142450723,"url":"https://finnhub.io/api/news?id=e3252f099c9816b69554fb1f1e82a6e7efbc910f3f518034a5d98b91f54affaa","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences, Inc. (NASDAQ:GILD) and Abbott Laboratories (NYSE:ABT) both return cash to shareholders through dividends, but the businesses supporting those payouts look very different. Gilead is currently growing faster, powered by an HIV franchise that continues to gain momentum, while Abbott is offering considerably more diversification across medical devices, diagnostics, nutrition and established pharmaceuticals, as […]","category":"company","datetime":1790550968,"headline":"Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?"}, {"id":142450686,"url":"https://finnhub.io/api/news?id=b45cbb1348c4ca87e48b1167d543852c03ceb85b9d51e0a86598de6c39628c4a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences, Inc. (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ) offer investors two very different versions of pharmaceutical growth. Gilead is expanding faster, powered by an HIV franchise that continues to gain momentum, while Johnson & Johnson isn’t growing as quickly, but its portfolio stretches across pharmaceuticals and MedTech, giving it more ways to absorb weakness […]","category":"company","datetime":1790550765,"headline":"Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification?"}, {"id":142450725,"url":"https://finnhub.io/api/news?id=f47f4366f4cbc9bfecc28c9f8ccfcca3cf9f4e8e007fbfdb13f8a4549845e48a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Pfizer Inc. (NYSE:PFE) and Gilead Sciences, Inc. (NASDAQ:GILD) present investors with two very different forms of concentration risk. Pfizer needs newer medicines and its pipeline to offset revenue that will increasingly face generic and biosimilar competition, while Gilead has the opposite problem, where its biggest franchise is performing extremely well, but HIV accounts for roughly […]","category":"company","datetime":1790550557,"headline":"Gilead’s HIV Concentration or Pfizer’s Patent Cliff: Which Risk is Easier to Own?"}, {"id":142432371,"url":"https://finnhub.io/api/news?id=403589f5a28b768b40e6b9e54ab5a5d2aa8836e772aecee6e6c1fa8830560d81","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"GILD","summary":"Get the weekly summary of dividend changes for Dividend Champions, Contenders & Challengers, plus upcoming ex-dividend and pay dates.","category":"company","datetime":1790377479,"headline":"Dividend Champion, Contender, And Challenger Highlights: Week September 27"}, {"id":142421742,"url":"https://finnhub.io/api/news?id=a07d38e192fa941e681aeeb3b0c0224f31aed5a0accfe1863cf64545f7a8922b","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536","source":"Benzinga","related":"GILD","summary":"This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often","category":"company","datetime":1790256910,"headline":"10 Health Care Stocks Whale Activity In Today’s Session"}, {"id":142365124,"url":"https://finnhub.io/api/news?id=4f8da2f8f429efeb7587bc2679fe4be78cd0979e03c7490cc84e8d7371bca325","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"GILD","summary":"Gilead Sciences is rated Sell, with a $97.46 fair value versus the $150.56 closing price, implying 35.3% downside. Click for more on the GILD stock.","category":"company","datetime":1790185993,"headline":"Gilead: HIV Growth Is Not Enough At The Current Price"}, {"id":142343869,"url":"https://finnhub.io/api/news?id=2bb88f53cb4d4703766d2fa783a1a72c4549b016bccb4007a1523e3807e81a50","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences (GILD) closed the most recent trading day at $152.67, moving +1.4% from the previous trading session.","category":"company","datetime":1790114405,"headline":"Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know"}, {"id":142331859,"url":"https://finnhub.io/api/news?id=f0fd854fd03d4c68ce3c8722ef717ee1e89bfcb009cd95556ec8381b4538c074","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.","category":"company","datetime":1790070586,"headline":"1 Cash-Producing Stock on Our Buy List and 2 We Find Risky"}, {"id":142340644,"url":"https://finnhub.io/api/news?id=033972e3854745199d16a43e53d2bfecd4f709597d776ba31ba77bbd14999b14","image":"https://image.cnbcfm.com/api/v1/image/108264668-1770841844066-gettyimages-2260574499-DOUSTDAR_INTERVIEW.jpeg?v=1770841930&w=1920&h=1080","source":"CNBC","related":"GILD","summary":"Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.","category":"company","datetime":1790052809,"headline":"Novo defends diversification push as CEO eyes deals beyond obesity"}, {"id":142314895,"url":"https://finnhub.io/api/news?id=5623f852d024055cb2d32412012583ba5ea052c3a4adde817ae8a074a9516832","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.","category":"company","datetime":1790006100,"headline":"BMY vs GILD: Which Biotech Stock Looks More Attractive Now?"}, {"id":142311278,"url":"https://finnhub.io/api/news?id=002d0b9e4660f8ba700936746f2c2dbab8a6ed55df5a0bceb3491fc5b41eefd6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"The drugmaker expects growth in line with industry peers as it works to rebuild its pipeline beyond obesity","category":"company","datetime":1789993229,"headline":"Novo Nordisk Stock Drops 5.6% as 2030 Goals Match Peers"}, {"id":142339172,"url":"https://finnhub.io/api/news?id=d51dbd7ada52e4ff52a0b9b92354d8553f2cbbdf9d3c7ec924f0a6c52e5bc1f7","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536","source":"Benzinga","related":"GILD","summary":"Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 4.6% on an annualized basis producing an average annual return of 16.24%. Currently, Gilead Sciences has a market capitalization of","category":"company","datetime":1789990232,"headline":"Here's How Much $1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth Today"}, {"id":142340649,"url":"https://finnhub.io/api/news?id=2059a9ef57dbfa8b8e82f89f3b9878fe009b8717089366ff4944c7fa9b32ff70","image":"https://image.cnbcfm.com/api/v1/image/108363158-17894901612026-09-15t163359z_2080430281_rc2qjna3z3zx_rtrmadp_0_novo-nordisk-strategy-townhall.jpeg?v=1789490250&w=1920&h=1080","source":"CNBC","related":"GILD","summary":"The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.","category":"company","datetime":1789964630,"headline":"Novo shares slide as drugmaker lays out post-Wegovy growth strategy"}, {"id":142289621,"url":"https://finnhub.io/api/news?id=8847aee5254d1cadb2e440ab092a52ca873646ec53eea5b614b1fffb4f31ad5c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"After sessions with Gilead’s leadership at Morgan Stanley’s 2026 Global Healthcare Conference, the bank reaffirmed its Overweight rating, and one franchise stood out.","category":"company","datetime":1789920180,"headline":"Why Morgan Stanley likes Gilead's HIV prevention play"}, {"id":142277829,"url":"https://finnhub.io/api/news?id=7a8453233558d1af67fd7a011617309053c83aa5e2b2f9526c58da60bb2d27d9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences (NasdaqGS:GILD) expanded its royalty-free voluntary licensing of once-yearly lenacapavir for HIV prevention to 120 high-incidence countries. The biopharma group signed a regional agreement with the Pan American Health Organization to widen access to twice-yearly lenacapavir across Latin America and the Caribbean. The PAHO partnership creates a direct pathway for 14 additional countries in the region to obtain lenacapavir for HIV prevention programs. Gilead's broader licensing...","category":"company","datetime":1789877873,"headline":"Why Is Gilead Sciences (GILD) Widening Lenacapavir Access Across 120 Countries?"}, {"id":142259763,"url":"https://finnhub.io/api/news?id=ce01359956cfa697fa14dbec0fa74d52e08052fef60abdd038c3a6770157df4d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences, Inc. (NASDAQ:GILD) has reached an agreement with the Pan American Health Organization (PAHO) to expand access to its twice-yearly HIV-prevention drug lenacapavir across Latin America and the Caribbean. The agreement creates a regional procurement pathway through PAHO for 14 countries, including Brazil, Mexico, Argentina, Colombia and Peru, that were outside Gilead’s existing voluntary […]","category":"company","datetime":1789750282,"headline":"Gilead Strengthens HIV Growth Platform with Expanded Latin America Access"}, {"id":142258035,"url":"https://finnhub.io/api/news?id=2f94d516b9514e3b44250c1ee5b2021449815a5a007c876cadfc15e9a7c16873","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.","category":"company","datetime":1789749060,"headline":"4 Biotech Stocks to Watch as Potential Takeover Targets"}, {"id":142255053,"url":"https://finnhub.io/api/news?id=be475871efb7e63509e6725d824caf28cb24c7bebd4aa0cd964870a91f29b1fb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.","category":"company","datetime":1789736700,"headline":"J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?"}, {"id":142254787,"url":"https://finnhub.io/api/news?id=9e36abb4736760f20f2560d69abeba3d6a402c6a5b6c3ebfc2d1ef95ab93e692","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1630128517/image_1630128517.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"GILD","summary":"Oncology spending may hit $441B by 2029 as growth slows from generics—see 5 underappreciated cancer stocks with catalysts and upside. Click for the picks.","category":"company","datetime":1789723352,"headline":"5 Undervalued Oncology Stocks Wall Street Is Overlooking"}, {"id":142235324,"url":"https://finnhub.io/api/news?id=b0d8c0f8c6a725b5bd6f5163684068f5c1476636c095f8b3dcdadec10e95f2b7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"MEXICO CITY, September 17, 2026--AIDS Healthcare Foundation (AHF), the world’s largest HIV care provider, welcomes a new agreement between Gilead Sciences and the Pan American Health Organization (PAHO) that could expand access to lenacapavir for HIV prevention in 14 countries across Latin America. The agreement represents a positive step toward expanding access in the region and a victory for civil society.","category":"company","datetime":1789684560,"headline":"Latin America’s PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF"}, {"id":142235325,"url":"https://finnhub.io/api/news?id=289ba3334c78c7143d9751ea6bad630a852e94208c3a5c796c6083e9ce09bd63","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.","category":"company","datetime":1789650004,"headline":"Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know"}, {"id":142197169,"url":"https://finnhub.io/api/news?id=e75f3b737d90025c607b605e7dfe339e2de02fc4e7e0e1232d8e9e290c3d211b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.","category":"company","datetime":1789568760,"headline":"Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America"}, {"id":142197168,"url":"https://finnhub.io/api/news?id=4ded9287680153405d14690cb18989c70c791fc2a8bd7ad575a7949ac7d765c8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences (NASDAQ:GILD) has expanded six existing royalty-free voluntary licensing agreements to include an investigational once-yearly formulation of lenacapavir for HIV prevention, the company announced. The expanded agreements cover 120 countries with high HIV incidence, primarily low- and lower-middle-income nations.","category":"company","datetime":1789566407,"headline":"Gilead Expands Lenacapavir Licensing Agreements to Include Once-Yearly HIV Prevention Formulation"}, {"id":142195305,"url":"https://finnhub.io/api/news?id=dafb6c5da8ed62d8268fa0cc1b15db1e1e09999cd531da589a3f6272e49de310","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"FOSTER CITY, Calif., September 16, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreements cover 120 high-incidence countries (which are primarily low- and lower-middle-income) and will support manufacturing readiness, technology transfer and future supply planning while th","category":"company","datetime":1789561800,"headline":"Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention"}, {"id":142168612,"url":"https://finnhub.io/api/news?id=41c20debab4892cfcc8e5df91f607b6ff849d71ca9681a6e3e5467d1f3dd040e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Healthcare stocks were edging lower late Tuesday afternoon, with the NYSE Healthcare Index and the S","category":"company","datetime":1789501922,"headline":"Sector Update: Healthcare Stocks Ease Late Afternoon"}, {"id":142168611,"url":"https://finnhub.io/api/news?id=05e03c437e22b4495a6f1a6b9692ef0350d02115e52fd82d5951e2fd56884682","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences (NASDAQ:GILD) executives outlined plans to expand the company’s HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief Executive Officer Dan O’Day describing the company as being at an “inflection point in value.” Speaking","category":"company","datetime":1789495361,"headline":"Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances"}, {"id":142165807,"url":"https://finnhub.io/api/news?id=5ade9a56eb375da8f28bf3012504f1590b9391ef3d521fba73f42d96f01bcaeb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Healthcare stocks were edging down Tuesday afternoon, with the NYSE Healthcare Index fractionally lo","category":"company","datetime":1789494294,"headline":"Sector Update: Healthcare Stocks Lower Tuesday Afternoon"}, {"id":142165808,"url":"https://finnhub.io/api/news?id=aab50ca76bc298dcbddb222504331db4702f2babfb6fb39ac0c29c9ffd5333ea","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"FOSTER CITY, Calif., September 15, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO Member States in Latin America and the Caribbean. Through PAHO’s Regional Revolving Funds, the agreement establishes a coordinated regional pathway to expand access to long-acting HIV prevention and support country-led eff","category":"company","datetime":1789485000,"headline":"Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean"}, {"id":142164888,"url":"https://finnhub.io/api/news?id=b835c9970ebeab2466dae19af131df5eb52315b5528b1066051cc561ce12090e","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"GILD","summary":"Gilead Sciences, Inc. (GILD) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 10:45 AM EDTCompany ParticipantsDaniel O'Day -...","category":"company","datetime":1789477898,"headline":"Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"}, {"id":142195687,"url":"https://finnhub.io/api/news?id=4f7d4f9e26fee45da8f4d0aa3374bb4b5c2eb3ee8b03f594d397b6ef95d5cde8","image":"","source":"Benzinga","related":"GILD","summary":"– Agreement Establishes a Regional Pathway Through PAHO’s Regional Revolving Funds to Support Country-Led Adoption of Long-Acting HIV Prevention –– Partnership Advances Gilead’s Global Access Strategy, Helping Turn","category":"company","datetime":1789470811,"headline":"Gilead And PAHO Partner To Expand Twice-Yearly Lenacapavir HIV Prevention Access Across Latin America And The Caribbean"}, {"id":142195688,"url":"https://finnhub.io/api/news?id=5559be0d8b3c9cb51da48c2bed670d13dfd8bb31bd9a772baee37d9a8efb3f6e","image":"","source":"Benzinga","related":"GILD","summary":"https://event.webcasts.com/starthere.jsp?ei=1776111&tp_key=7239e5582f&tp_special=8","category":"company","datetime":1789470595,"headline":"Gilead Exec Says HIV Market Growth Should Normalize To 2%-3% Within Next Couple Of Quarters"}, {"id":142195689,"url":"https://finnhub.io/api/news?id=6147d430c9b60762db277ef84f104128f1335c642705ff6bd63a16b7452fdb0b","image":"","source":"Benzinga","related":"GILD","summary":" - conference call","category":"company","datetime":1789470383,"headline":"Gilead Sciences Exec Says Weekly Oral HIV Prevention Drug Expected To Launch In Q1 2027"}, {"id":142162734,"url":"https://finnhub.io/api/news?id=4394075bfdfaa0607d0287d084dfdbfdf4fde8cf81315f0bc3b27c2e7263eb10","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"This article first appeared on GuruFocus. Gilead Sciences Inc (NASDAQ:GILD) recently announced a total dividend of $0.82 per share, with the ex-dividend date set for 2026-09-15. This upcoming distribution includes a $0.82 per share cash dividend payable on 2026-09-29.","category":"company","datetime":1789470075,"headline":"Gilead Sciences Inc's Dividend Analysis"}, {"id":142148466,"url":"https://finnhub.io/api/news?id=3a55a81182ae3c5e5b4374a25b9a6efef8453c8ec54bf82e452ff204106c0074","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences has delivered a powerful 5 year run in its share price, and fresh headlines around new research facilities and HIV treatments keep attention firmly on its growth story. With the stock now at US$146.42, the live question for investors is whether that market value lines up with what the business is generating in sales. The share price is up 146.6% over 5 years, which puts real pressure on the current sales base to justify where the stock now trades. The new Foster City research...","category":"company","datetime":1789427954,"headline":"Is Gilead Sciences (GILD) Reasonable Given Its Sales Base?"}, {"id":142142918,"url":"https://finnhub.io/api/news?id=8a116fdbee1d8eb7ce3ac2da5e876c8b135cc3f4df70260953188f14db7782b0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.42, denoting a +1.88% move from the preceding trading day.","category":"company","datetime":1789423203,"headline":"Gilead Sciences (GILD) Gains As Market Dips: What You Should Know"}
data_source finnhub_news_keyword_model
article_count 8
negative_hits 0
positive_hits 2
recomputed_at_score true
sentiment_score_raw 0.6
source_article_count 79
discarded_article_count 61
sentimentPoints 4

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 2.5 5/110 50% 2.5
資金流 8.4 20/110 42% 8.4
市場環境 12.6 15/110 84% 12.6
催化劑 2 20/110 10% 2
風險管理 7.4 10/110 74% 7.4
技術信號 19.2 30/110 64% 19.2
情緒分析 4 10/110 40% 4

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 9/50
ret_5d 0.0401
max_score 50
max_total 50
raw_total 9
vcp_bonus 0
vol_ratio 0.8974
ret_points 8
vol_points 0
range_ratio 0.6949
volat_points 0
day_range_pct 0.0164
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 1
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.6

details

atrPct 2.2436
turnoverUsdM 786.91
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.GILD
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 143.68

strength_details

ma_score 1.5
atr_score 2
rsi_score 1
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1.1
stop_loss_percent 4.5
take_profit_price 157.9515
target_multiplier 1.6
technical_strength 1.38
take_profit_percent 5
positionPoints 1.6
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 4.4871
diversificationPoints 2

Calculation audit log

基本面分析總分: 2.5/5分
資金流分析總分: 8.4/20分
市場環境分析總分: 12.6/15分
催化劑分析: 2/20分
風險管理總分: 7.4/10分
技術信號分析總分: 19.2/30分
情緒分析: 4/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 92.86
atr
atr 3.375
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.24
cci
rule Cursor_18.24 CCI bands
level 適中偏強
score 8
value 61.65
cmf
rule Cursor_18.24 CMF bands
level 平衡
score 4
value 0.0479
kdj
d 45.39
j 91.47
k 60.75
rule Cursor_18.24 K/D cross
score 6
signal 強金叉
mfi
rule Cursor_18.24 MFI bands
level 弱流入
score 4
value 43.28
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 2
trend 資金流出
value -1985371
recentSlope -1454347.1
previousSlope 103920
rsi
value 44.71
sar
rule Cursor_18.24 Parabolic SAR
score 8
trend 上升
value 142.7768
position SAR喺價下
distancePct 5.09
previousTrend 上升
ma50
value 145.116
macd
macd 0.7107
trend 中性偏多
signal 0.9273
histogram -0.2166
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 6
value 149.1146
position 連續1-2日>VWAP
consecutiveAbove 2
volume
rule Cursor_18.24 volume ratio
level 無力
ratio 0.9
score 4
avgVolume 5844674
currentVolume 5231071
derived
ma20 148.9695
ma50 145.116
prevClose 151.17
avgVolume10 5064227
avgVolume20 5844674
changePercent -0.49
avgVolumeForScore 5844674
ma_cross
ma20 148.9695
ma50 145.116
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 148.7685
prevMa50 144.7116
spreadPct 2.66
isVolumeBreakout false
bollinger
lower 143.826
upper 154.113
position 上半部
rsi_short
value 84.74
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 0.9

Raw calculation JSON

 
{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.2435685862905395,
        "turnoverUsdM": 786.90995821929,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.GILD",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 143.68,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 4.5,
      "take_profit_price": 157.9515,
      "target_multiplier": 1.6,
      "technical_strength": 1.38,
      "take_profit_percent": 5
    },
    "positionPoints": 1.6,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.487137172581079,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 65.1,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 56.1,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 9
  },
  "market": {
    "ma20": 148.9695,
    "ma50": 145.116,
    "close": 150.43,
    "prevClose": 151.17,
    "avgVolume20": 5844674,
    "volumeRatio": 0.9,
    "changePercent": -0.49
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 9,
    "details": {
      "ret_5d": 0.04010226094171343,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 9,
      "vcp_bonus": 0,
      "vol_ratio": 0.8974039798494282,
      "ret_points": 8,
      "vol_points": 0,
      "range_ratio": 0.6948557049493712,
      "volat_points": 0,
      "day_range_pct": 0.01635305566396685,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 65.1,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 50,
        "contribution": 2.5
      },
      {
        "raw": 8.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 42,
        "contribution": 8.4
      },
      {
        "raw": 12.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 84,
        "contribution": 12.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.4,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 74,
        "contribution": 7.4
      },
      {
        "raw": 19.2,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 64,
        "contribution": 19.2
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 56.1,
    "details": [
      "基本面分析總分: 2.5/5分",
      "資金流分析總分: 8.4/20分",
      "市場環境分析總分: 12.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.4/10分",
      "技術信號分析總分: 19.2/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.5,
      "資金流": 8.4,
      "市場環境": 12.6,
      "情緒分析": 4,
      "技術信號": 19.2,
      "風險管理": 7.4
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0,
          "epsPoints": 0.6,
          "roePoints": 0,
          "debtPoints": 0.3,
          "marginPoints": 0,
          "turnoverUsdM": 786.90995821929,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 1.6,
          "obvPoints": 0.8,
          "vwapPoints": 2.4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.GILD",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "優秀",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 14.84
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 739.38449965,
                "ma50": 725.6844004000002,
                "name": "QQQ",
                "close": 746.039978,
                "points": 2
              },
              "spy": {
                "ma20": 768.8379970499998,
                "ma50": 768.1957967800001,
                "name": "SPY",
                "close": 778.099976,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.2435685862905395,
          "atrPoints": 3,
          "cciPoints": 3.2,
          "vixPoints": 2.4,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142820058,
                "url": "https://finnhub.io/api/news?id=9387852c7120fcdd29adfdb910505d1715b53c6deb397f2a103e66cc75fb8070",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) shares are up more than 24% this year, ahead of the S&P 500’s 14%. Gilead makes HIV, liver disease and cancer drugs. The stock is part of our coverage of the 8 best-performing stock picks by Claude AI in 2026. Why Gilead Stock Is Up Gilead Q2 sales rose 10% year […]",
                "category": "company",
                "datetime": 1791812886,
                "headline": "Can Gilead (GILD) Stock Continue Rising in 2027?"
              },
              {
                "id": 142800040,
                "url": "https://finnhub.io/api/news?id=c8aa46e1dffb5aa548e1d5eb4f7927364c339382e45bda6fd9b4941975c85a4f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences stock has delivered a strong multi year run, which puts a spotlight on whether the current share price still lines up with the company’s sales base. With fresh headlines on earnings, partnerships and pipeline progress, the real question for investors is how much of Gilead’s revenue story is already reflected in today’s valuation. Over the past 5 years, Gilead Sciences has returned 167.1%. Anyone looking at the stock now is asking how that kind of gain squares with its sales...",
                "category": "company",
                "datetime": 1791699157,
                "headline": "Is Gilead Sciences (GILD) Undervalued After Strong Q2 Sales?"
              },
              {
                "id": 142767972,
                "url": "https://finnhub.io/api/news?id=af60f572cf52793220433c93cd385c0045a9e6799c65229ac00d8dfd2ffe59ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) closed the most recent trading day at $151.17, moving +2.77% from the previous trading session.",
                "category": "company",
                "datetime": 1791579604,
                "headline": "Gilead Sciences (GILD) Laps the Stock Market: Here's Why"
              },
              {
                "id": 142732213,
                "url": "https://finnhub.io/api/news?id=3a09402950476f7fcd62242a96163f1a6fd9721187ff48031e02e64cda88ce45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers.",
                "category": "company",
                "datetime": 1791483849,
                "headline": "Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)"
              },
              {
                "id": 142633635,
                "url": "https://finnhub.io/api/news?id=1ee8e3d0524fdbb67e1b948471d2d665c7caaa16cfef8d1ed997e51aab395757",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) passes a high-quality dividend screen with a 3.98% yield, strong profitability, cheap valuation, and key risks to watch.",
                "category": "company",
                "datetime": 1791199251,
                "headline": "Gilead Sciences (NASDAQ:GILD) Offers Dividend Investors Quality Income and Valuation Support"
              },
              {
                "id": 142593657,
                "url": "https://finnhub.io/api/news?id=5643f6193002955ede3dce056dee6d1f7e7ad82b31f17d9f60e3e061f62c74c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) closed the most recent trading day at $144.74, moving 1.87% from the previous trading session.",
                "category": "company",
                "datetime": 1790974205,
                "headline": "Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know"
              },
              {
                "id": 142583871,
                "url": "https://finnhub.io/api/news?id=d2a40d543e277ab2d63941b69cc09eb6a30b1761af305596648930b9bf5b9b47",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) earns a 10/10 Technical Rating and 8/10 Setup Quality on ChartMill's breakout screen. See entry, stop, and risk levels.",
                "category": "company",
                "datetime": 1790935861,
                "headline": "Gilead Sciences (NASDAQ:GILD) Combines Top Technical Strength With a High-Quality Breakout Setup"
              },
              {
                "id": 142557827,
                "url": "https://finnhub.io/api/news?id=000dade194eb1687191ad8725a86ca0b193f09fd993e8590b624ef11c675f376",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1790856005,
                "headline": "Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It"
              }
            ],
            "raw_source": [
              {
                "id": 142824587,
                "url": "https://finnhub.io/api/news?id=4ada72fac9123a59143a240d812a2ab69d3c89f7ae6796e066c81830e7e4ce67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobrutideg combination strategy with initiation of recruiting for the Phase 1b/2 NX-5948-203 study Earned $27M from Gilead, Pfizer and Sanofi collaborations, including a $10M milestone from Sanofi for first patient dosed in the STAT6 degrader Phase 1 trial Advanced NX-1607 into Phase 1b expansion cohorts in MSS CRC, NSCLC, CRPC and melanoma with",
                "category": "company",
                "datetime": 1791835500,
                "headline": "Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update"
              },
              {
                "id": 142821709,
                "url": "https://finnhub.io/api/news?id=276bb6be8569f3edf6bab8119b219d4362fa18e04700f2f3471617ab034cd050",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences' (GILD) HIV prevention drug Yeztugo's long-term growth outlook is supported by a phy",
                "category": "company",
                "datetime": 1791817629,
                "headline": "Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says"
              },
              {
                "id": 142820058,
                "url": "https://finnhub.io/api/news?id=9387852c7120fcdd29adfdb910505d1715b53c6deb397f2a103e66cc75fb8070",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) shares are up more than 24% this year, ahead of the S&P 500’s 14%. Gilead makes HIV, liver disease and cancer drugs. The stock is part of our coverage of the 8 best-performing stock picks by Claude AI in 2026. Why Gilead Stock Is Up Gilead Q2 sales rose 10% year […]",
                "category": "company",
                "datetime": 1791812886,
                "headline": "Can Gilead (GILD) Stock Continue Rising in 2027?"
              },
              {
                "id": 142805485,
                "url": "https://finnhub.io/api/news?id=018c09de44fa21b891968fbffafbc07e0dd112a55fd397ec10cf1709e1997a4a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) has had a considerably better year than the broader market. The stock has surged by over 24% since the start of the year, compared with a 14% return for the S&P 500. The rally has changed the valuation equation. Yahoo Finance recently put Gilead’s normalized forward P/E at approximately 15.5 times. […]",
                "category": "company",
                "datetime": 1791724616,
                "headline": "Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive?"
              },
              {
                "id": 142800040,
                "url": "https://finnhub.io/api/news?id=c8aa46e1dffb5aa548e1d5eb4f7927364c339382e45bda6fd9b4941975c85a4f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences stock has delivered a strong multi year run, which puts a spotlight on whether the current share price still lines up with the company’s sales base. With fresh headlines on earnings, partnerships and pipeline progress, the real question for investors is how much of Gilead’s revenue story is already reflected in today’s valuation. Over the past 5 years, Gilead Sciences has returned 167.1%. Anyone looking at the stock now is asking how that kind of gain squares with its sales...",
                "category": "company",
                "datetime": 1791699157,
                "headline": "Is Gilead Sciences (GILD) Undervalued After Strong Q2 Sales?"
              },
              {
                "id": 142772223,
                "url": "https://finnhub.io/api/news?id=d7341b07311e0a7aadb936df0d126442fa321eed83f51e517867f131ac1fb044",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) generated free cash flow equal to 7.1% of its market value over the last twelve months. The median S&P 500 company yielded just 4.5% over the same period. A yield that high means one of two things: the business is either trading at a steep discount, or the market expects it to shrink. So why are investors paying so little for Gilead's cash.",
                "category": "company",
                "datetime": 1791593224,
                "headline": "Why Is Everyone Ignoring Gilead Stock's High Cash Yield?"
              },
              {
                "id": 142767972,
                "url": "https://finnhub.io/api/news?id=af60f572cf52793220433c93cd385c0045a9e6799c65229ac00d8dfd2ffe59ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) closed the most recent trading day at $151.17, moving +2.77% from the previous trading session.",
                "category": "company",
                "datetime": 1791579604,
                "headline": "Gilead Sciences (GILD) Laps the Stock Market: Here's Why"
              },
              {
                "id": 142732213,
                "url": "https://finnhub.io/api/news?id=3a09402950476f7fcd62242a96163f1a6fd9721187ff48031e02e64cda88ce45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers.",
                "category": "company",
                "datetime": 1791483849,
                "headline": "Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)"
              },
              {
                "id": 142726119,
                "url": "https://finnhub.io/api/news?id=8d63381bbde91898ccdd27d5aa01cfb39426588cb7095723b0067b83509ee531",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Cognizant Technology Solutions (NasdaqGS: CTSH) announced multi-year AI-focused partnerships with Gilead Sciences and SITA. The Gilead agreement targets AI-enabled DevOps and finance transformation programs using Cognizant's cloud and automation capabilities. The SITA collaboration focuses on applying Cognizant's AI tools across global air transport technology systems and related services. Cognizant also introduced Cognizant Activate, a program aimed at speeding AI adoption for emerging...",
                "category": "company",
                "datetime": 1791458126,
                "headline": "What Is Cognizant Technology Solutions (CTSH) Signaling With Its Latest AI Push?"
              },
              {
                "id": 142728774,
                "url": "https://finnhub.io/api/news?id=0e8e95897c3fe2fcf0ba7270fedde6c15cf641d02a653be38505f5776ac2c319",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $123 to $126.",
                "category": "company",
                "datetime": 1791453693,
                "headline": "RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $126"
              },
              {
                "id": 142728775,
                "url": "https://finnhub.io/api/news?id=66241126a5570aa7f36882c20ca675816372ae8e0a1e173404131fdca173b161",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.",
                "category": "company",
                "datetime": 1791441772,
                "headline": "Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target"
              },
              {
                "id": 142701393,
                "url": "https://finnhub.io/api/news?id=da94b08ce470a3378e56e75d8c59b4f34f9e709c3a28f65cbc1d5af53a06c7b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Nurix Therapeutics, Inc. recently announced that it has extended by two years the research term for an undisclosed oncology program under its ongoing collaboration with Gilead Sciences, originally established in 2019 to develop E3 ligase–based protein degradation therapies. This extension underscores continued progress in a partnership that could earn Nurix up to approximately US$1.30 billion in potential payments, plus tiered royalties on any future commercial products, with options for...",
                "category": "company",
                "datetime": 1791415027,
                "headline": "Is Extending the Gilead E3 Ligase Collaboration Altering The Investment Case For Nurix Therapeutics (NRIX)?"
              },
              {
                "id": 142701310,
                "url": "https://finnhub.io/api/news?id=be0a7e3fa760ed5f0a5c52227739c617a8ce6b41a96fbf2c446e8d620797eaa5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Exelixis (EXEL) stock has returned 46% over the past twelve months, compared with 17.8% for the S&P 500. The company has aggressively repurchased its own stock, reducing its total share count by 21% over the last three years. Because fewer shares remain in circulation, each one lays claim to a larger slice of the profit. So how much is that buyback adding to each Exelixis share you own.",
                "category": "company",
                "datetime": 1791414880,
                "headline": "Is Exelixis Stock Engineered To Make You Money?"
              },
              {
                "id": 142700439,
                "url": "https://finnhub.io/api/news?id=da80826b64e80f1594dae15b7d87a27233f733bf721bc6594d3507759e01fcbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Abbott Laboratories (NYSE:ABT) is a business that is not showcasing any rapid growth trends. However, what makes it an attractive investment prospect is the company’s consistent track record of incremental dividends, with 411 consecutive quarterly payouts since 1924. Along with the company’s underlying business mix, it makes Abbott a suitable investment for dividend hunters. The […]",
                "category": "company",
                "datetime": 1791406181,
                "headline": "Is Abbott Laboratories (ABT) a Dividend Bargain After Its 2026 Selloff?"
              },
              {
                "id": 142694679,
                "url": "https://finnhub.io/api/news?id=dfa716cf5868aea56979acaaf21f82e903edf0b1c71862029996a12e650ff5cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The Dow Jones index drops 450 points Wednesday as Treasury yields jump. The Fed minutes are due later in the day.",
                "category": "company",
                "datetime": 1791383028,
                "headline": "Stock Market Today: Dow Tumbles 450 Points As Yields Jump; Fed Minutes On Deck (Live Coverage)"
              },
              {
                "id": 142728776,
                "url": "https://finnhub.io/api/news?id=dbd10737ccf082ae93a8fe65116ea381d0c97502c38963e0c51442d6e7122140",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Truist Securities  analyst Gregory Renza   maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $150 to $158.",
                "category": "company",
                "datetime": 1791377252,
                "headline": "Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158"
              },
              {
                "id": 142728777,
                "url": "https://finnhub.io/api/news?id=0624c05c74a0897e9c717dd9efeef8b3ef8715fe951533f7dce139900d0d6909",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "JP Morgan  analyst Chris Schott   maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $160 to $170.",
                "category": "company",
                "datetime": 1791376523,
                "headline": "JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $170"
              },
              {
                "id": 142696751,
                "url": "https://finnhub.io/api/news?id=8308e808fdc23788f000e70153d42c9acc20ae41a151b1ef8a6ad65aa86d7bfe",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Morgan Stanley  analyst Matthew Harrison   maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $165 to $163.",
                "category": "company",
                "datetime": 1791369244,
                "headline": "Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163"
              },
              {
                "id": 142688722,
                "url": "https://finnhub.io/api/news?id=4608d9e544ba0975401ceb401b4517d7267b0fe2a1145ef60aa3e03161a0b159",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The arrangement will see Cognizant combine its life sciences knowledge with technical services to aid Gilead's processes.",
                "category": "company",
                "datetime": 1791361316,
                "headline": "Gilead Sciences signs five-year DevOps agreement with Cognizant"
              },
              {
                "id": 142663035,
                "url": "https://finnhub.io/api/news?id=0d8e033e32e58d924869cfeb3451cdfdc3a2e75cc7006065c6c6eb170d96ead5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapiesTEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of biopharmaceutical executive Laura Hamill to its Board of Directors, effective December 1, 2026. Ms. Hamill brings more than 35 years of global commercial, market",
                "category": "company",
                "datetime": 1791288000,
                "headline": "Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise"
              },
              {
                "id": 142664221,
                "url": "https://finnhub.io/api/news?id=706faaac00d6e5ed27a643901c5203ca14fd47a9c44c4692b3c93a9cc1da79ed",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2236050381/image_2236050381.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Gilead Sciences remains a Hold: HIV drives Q2 growth, but oncology/CAR‑T lags and costly M&A strains FCF. Click to read this latest analysis of GILD stock.",
                "category": "company",
                "datetime": 1791282950,
                "headline": "Gilead: Buying Growth Isn't Free, And The Discounted Cash Flow Model Knows It"
              },
              {
                "id": 142639194,
                "url": "https://finnhub.io/api/news?id=7933b7eae46aa038abbaf842273cb447cd5fdc97b16d1c6884ce82e32a3ccf64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Compugen (NASDAQ:CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated antigen, or TAA, research during a company update event. President and Chief Executive Officer Er",
                "category": "company",
                "datetime": 1791234127,
                "headline": "Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets"
              },
              {
                "id": 142638690,
                "url": "https://finnhub.io/api/news?id=770bacb7f8482a023eeb2dc94987553cc4ae2ef4df216448c7835c9cf3b21dcf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cara Bauer, Ph.D., has been named Executive Vice President, Chief People Officer. Ms. Bauer will assume responsibility for the company's Human Resources organization, effective Oct. 5, succeeding Amy Wireman, who is retiring.",
                "category": "company",
                "datetime": 1791230700,
                "headline": "BioMarin Appoints Cara Bauer as Chief People Officer"
              },
              {
                "id": 142666467,
                "url": "https://finnhub.io/api/news?id=d4ac3a4a79016711df083f84db8896c82df32e71f0e91404648636116ee3dc93",
                "image": "https://image.cnbcfm.com/api/v1/image/108317496-1780677508197-gettyimages-2279271508-US_STOCKS.jpeg?v=1780677968&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.",
                "category": "company",
                "datetime": 1791215070,
                "headline": "AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment "
              },
              {
                "id": 142633635,
                "url": "https://finnhub.io/api/news?id=1ee8e3d0524fdbb67e1b948471d2d665c7caaa16cfef8d1ed997e51aab395757",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) passes a high-quality dividend screen with a 3.98% yield, strong profitability, cheap valuation, and key risks to watch.",
                "category": "company",
                "datetime": 1791199251,
                "headline": "Gilead Sciences (NASDAQ:GILD) Offers Dividend Investors Quality Income and Valuation Support"
              },
              {
                "id": 142633238,
                "url": "https://finnhub.io/api/news?id=136a49bfb05df5a9089c4ef5e21f5cfa9a33f83fe036d3e05b121b5dc1d46c75",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Two-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Nurix and Gilead Sciences have agreed to extend th",
                "category": "company",
                "datetime": 1791198000,
                "headline": "Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences"
              },
              {
                "id": 142634785,
                "url": "https://finnhub.io/api/news?id=b09602f8cd28237e64b2feb5ab368e47947df589ef7f11b385fd04a49f5fb127",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Nurix and",
                "category": "company",
                "datetime": 1791184220,
                "headline": "Nurix Gets $10M As Gilead Extends Drug Discovery Deal"
              },
              {
                "id": 142593657,
                "url": "https://finnhub.io/api/news?id=5643f6193002955ede3dce056dee6d1f7e7ad82b31f17d9f60e3e061f62c74c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) closed the most recent trading day at $144.74, moving 1.87% from the previous trading session.",
                "category": "company",
                "datetime": 1790974205,
                "headline": "Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know"
              },
              {
                "id": 142591878,
                "url": "https://finnhub.io/api/news?id=ab2ab560f4925378beb465ae0245e168c9c54c5752738e6f441da4f852ff4daa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Legend Biotech's (LEGN) multiple myeloma therapy Carvykti is facing growing competitive pressure as",
                "category": "company",
                "datetime": 1790960724,
                "headline": "Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says"
              },
              {
                "id": 142583871,
                "url": "https://finnhub.io/api/news?id=d2a40d543e277ab2d63941b69cc09eb6a30b1761af305596648930b9bf5b9b47",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) earns a 10/10 Technical Rating and 8/10 Setup Quality on ChartMill's breakout screen. See entry, stop, and risk levels.",
                "category": "company",
                "datetime": 1790935861,
                "headline": "Gilead Sciences (NASDAQ:GILD) Combines Top Technical Strength With a High-Quality Breakout Setup"
              },
              {
                "id": 142571013,
                "url": "https://finnhub.io/api/news?id=6758043f688f5542b6b2266dafaa9d9f866fb6e649d41d2479708fe276cddfa4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead shares are up 35% since Barron’s highlighted them, but our catalysts have yet to fully play out.",
                "category": "company",
                "datetime": 1790907900,
                "headline": "More Upside Awaits for Gilead Sciences Stock. Stay Invested."
              },
              {
                "id": 142557827,
                "url": "https://finnhub.io/api/news?id=000dade194eb1687191ad8725a86ca0b193f09fd993e8590b624ef11c675f376",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1790856005,
                "headline": "Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 142524905,
                "url": "https://finnhub.io/api/news?id=6dc0243d4d8773f3b636e269fc5c987d4f33de8084d0d43758910c07cba58ac4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "In the latest trading session, Gilead Sciences (GILD) closed at $149.45, marking a -1.21% move from the previous day.",
                "category": "company",
                "datetime": 1790802004,
                "headline": "Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors"
              },
              {
                "id": 142512602,
                "url": "https://finnhub.io/api/news?id=37a1437e25f832cb49b993def235bdaf39695b5184d86e5c9fd31392f0d35df6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding clinical trials, and increased investment, while high costs and adverse effects remain barriers. Yescarta led the product market in 2025, hospitals were the largest end-user segment, and Asia Pacific is forecast to record the fastest growth through 2031.Dublin, Sept. 30, 2026",
                "category": "company",
                "datetime": 1790758020,
                "headline": "CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J"
              },
              {
                "id": 142519387,
                "url": "https://finnhub.io/api/news?id=687625e0f538d148fbd8ba992f2b1d8d80bf64384c725456d7bf8e3272166362",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/30/Former-President-Bill-Clinton-at-an-even.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Clinton warns abrupt HIV funding shifts could disrupt treatment and prevention, saying “a deadline isn’t a transition plan” and lives could be at risk.",
                "category": "company",
                "datetime": 1790745982,
                "headline": "Bill Clinton Sounds Alarm on HIV Funding: ‘Cheaper Medicines Mean Nothing If They Never Reach People’"
              },
              {
                "id": 142495911,
                "url": "https://finnhub.io/api/news?id=6533df3c2a8cdaff76083d569ab9807c7a728ed4612ae794478ac3f4b06bbef4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "BOSTON, September 29, 2026--Sware, Inc., the company behind the Res_Q, the AI-powered validation platform, and provider of GxP compliance solutions, today announced the appointment of Mark Hill to its Board of Directors.",
                "category": "company",
                "datetime": 1790686800,
                "headline": "Former Gilead CIO and CSL Chief Digital & Information Officer Mark Hill Joins Sware Board of Directors"
              },
              {
                "id": 142489003,
                "url": "https://finnhub.io/api/news?id=5a4e02a411bac236db5d78e54ee8716b187340eb56fb0a2c23a7c7fcfd2c7fc3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "AI, computational design and high-throughput screening are accelerating discovery, while targeted therapies, outsourcing and Asia-Pacific expansion create opportunities.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- \"Small Molecule Drug Discovery - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global small molecule drug discovery market was valued at US$61.5 billion in 2024 and is projected to reach US$100 billion by 2030, expanding at a compound annual g",
                "category": "company",
                "datetime": 1790673720,
                "headline": "Small Molecule Drug Discovery - Global Strategic Business Report Forecasts Growth from $61.5B (2024) to $100B by 2030, Profiling AstraZeneca, Gilead Sciences, Merck & Pfizer"
              },
              {
                "id": 142479811,
                "url": "https://finnhub.io/api/news?id=0714d67165220c8b178a13db884659ebba3b5e3fa2614bf91c2118312f3effd4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2244980373/image_2244980373.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Pfizer has a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. Find out why PFE stock is a Buy.",
                "category": "company",
                "datetime": 1790649185,
                "headline": "Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough"
              },
              {
                "id": 142472052,
                "url": "https://finnhub.io/api/news?id=488e40a32cb2988bc5000c8d285752cf0d607b375cc72d91f99ffe688692a18c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "On September 16, Gilead Sciences, Inc. (NASDAQ:GILD) expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to cover an investigational once-yearly formulation for HIV pre-exposure prophylaxis (PrEP). Covering 120 high-incidence, lower-income countries, the expanded framework aims to accelerate manufacturing readiness and technology transfer during the ongoing Phase 3 PURPOSE 365 study. Following […]",
                "category": "company",
                "datetime": 1790639523,
                "headline": "Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase?"
              },
              {
                "id": 142470291,
                "url": "https://finnhub.io/api/news?id=c1a29e6923dd60319cf3d8cf5214d780ef3c4e0ca7128a19e93e684c9184dcf8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "At first glance, Gilead Sciences, Inc. (NASDAQ:GILD) and Intuitive Surgical, Inc. (NASDAQ:ISRG) don’t make for the most obvious comparison. One sells medicines led by a massive HIV franchise, while the other has built its business around robotic surgery. Yet both have given investors a similar reason to pay attention this year, which is that growth […]",
                "category": "company",
                "datetime": 1790623645,
                "headline": "Gilead vs. Intuitive Surgical: Which Healthcare Stock Offers the Better Risk-Adjusted Upside?"
              },
              {
                "id": 142470289,
                "url": "https://finnhub.io/api/news?id=a7083a919d52bb2392d245f7cc8b44ce2561bdc6e2c5dccbf125b8b71a586848",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) and Danaher Corporation (NYSE:DHR) are both showing signs of stronger growth, but they are getting there in very different ways. Gilead already has momentum, which is supported by its HIV business that is expanding at a double-digit rate, with newer products contributing more and resulting in management raising its sales outlook. […]",
                "category": "company",
                "datetime": 1790621106,
                "headline": "Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?"
              },
              {
                "id": 142470257,
                "url": "https://finnhub.io/api/news?id=cf5570cdb7032e4ea4fe0efe4335287bed3d60c8fc46c4df6b5504877c967f47",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) and Thermo Fisher Scientific Inc. (NYSE:TMO) are benefiting from two very different sources of growth. Gilead’s momentum is being driven primarily by its HIV portfolio, where established medicines and newer products are expanding rapidly. Thermo Fisher, meanwhile, is beginning to benefit from strengthening customer activity across the life-sciences markets it serves […]",
                "category": "company",
                "datetime": 1790618905,
                "headline": "Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?"
              },
              {
                "id": 142466403,
                "url": "https://finnhub.io/api/news?id=c672a63edc3419bbb2970893f2d87cb95bad7b6ae639d9cb2283dc5a7df67aa9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) has put fresh numbers on the table, raising its 2026 sales outlook and lifting its quarterly dividend by 3.8%, a combination that tends to grab investor attention. That guidance change is landing in a stock that already has momentum behind it, with a 90 day share price return of 19.46% and a year to date move of 24.12%. Over the longer haul, Gilead Sciences has delivered a 37.33% 1 year total shareholder return and triple digit total shareholder returns over 3 and 5...",
                "category": "company",
                "datetime": 1790601094,
                "headline": "Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend?"
              },
              {
                "id": 142450685,
                "url": "https://finnhub.io/api/news?id=c271b58558e32907ae90c0fb83fb80fa9e21bae8fe51ff068d9475cac631a4e5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) and Medtronic plc (NYSE:MDT) both combine growing healthcare businesses with regular cash returns to shareholders, but the sources of that growth look very different. Gilead is being propelled by its dominant HIV portfolio, where several products are expanding rapidly. On the other hand, Medtronic’s growth is spread across a much broader […]",
                "category": "company",
                "datetime": 1790551205,
                "headline": "Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income?"
              },
              {
                "id": 142450723,
                "url": "https://finnhub.io/api/news?id=e3252f099c9816b69554fb1f1e82a6e7efbc910f3f518034a5d98b91f54affaa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) and Abbott Laboratories (NYSE:ABT) both return cash to shareholders through dividends, but the businesses supporting those payouts look very different. Gilead is currently growing faster, powered by an HIV franchise that continues to gain momentum, while Abbott is offering considerably more diversification across medical devices, diagnostics, nutrition and established pharmaceuticals, as […]",
                "category": "company",
                "datetime": 1790550968,
                "headline": "Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?"
              },
              {
                "id": 142450686,
                "url": "https://finnhub.io/api/news?id=b45cbb1348c4ca87e48b1167d543852c03ceb85b9d51e0a86598de6c39628c4a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ) offer investors two very different versions of pharmaceutical growth. Gilead is expanding faster, powered by an HIV franchise that continues to gain momentum, while Johnson & Johnson isn’t growing as quickly, but its portfolio stretches across pharmaceuticals and MedTech, giving it more ways to absorb weakness […]",
                "category": "company",
                "datetime": 1790550765,
                "headline": "Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification?"
              },
              {
                "id": 142450725,
                "url": "https://finnhub.io/api/news?id=f47f4366f4cbc9bfecc28c9f8ccfcca3cf9f4e8e007fbfdb13f8a4549845e48a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Pfizer Inc. (NYSE:PFE) and Gilead Sciences, Inc. (NASDAQ:GILD) present investors with two very different forms of concentration risk. Pfizer needs newer medicines and its pipeline to offset revenue that will increasingly face generic and biosimilar competition, while Gilead has the opposite problem, where its biggest franchise is performing extremely well, but HIV accounts for roughly […]",
                "category": "company",
                "datetime": 1790550557,
                "headline": "Gilead’s HIV Concentration or Pfizer’s Patent Cliff: Which Risk is Easier to Own?"
              },
              {
                "id": 142432371,
                "url": "https://finnhub.io/api/news?id=403589f5a28b768b40e6b9e54ab5a5d2aa8836e772aecee6e6c1fa8830560d81",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Get the weekly summary of dividend changes for Dividend Champions, Contenders & Challengers, plus upcoming ex-dividend and pay dates.",
                "category": "company",
                "datetime": 1790377479,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week September 27"
              },
              {
                "id": 142421742,
                "url": "https://finnhub.io/api/news?id=a07d38e192fa941e681aeeb3b0c0224f31aed5a0accfe1863cf64545f7a8922b",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1790256910,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 142365124,
                "url": "https://finnhub.io/api/news?id=4f8da2f8f429efeb7587bc2679fe4be78cd0979e03c7490cc84e8d7371bca325",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Gilead Sciences is rated Sell, with a $97.46 fair value versus the $150.56 closing price, implying 35.3% downside. Click for more on the GILD stock.",
                "category": "company",
                "datetime": 1790185993,
                "headline": "Gilead: HIV Growth Is Not Enough At The Current Price"
              },
              {
                "id": 142343869,
                "url": "https://finnhub.io/api/news?id=2bb88f53cb4d4703766d2fa783a1a72c4549b016bccb4007a1523e3807e81a50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) closed the most recent trading day at $152.67, moving +1.4% from the previous trading session.",
                "category": "company",
                "datetime": 1790114405,
                "headline": "Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know"
              },
              {
                "id": 142331859,
                "url": "https://finnhub.io/api/news?id=f0fd854fd03d4c68ce3c8722ef717ee1e89bfcb009cd95556ec8381b4538c074",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
                "category": "company",
                "datetime": 1790070586,
                "headline": "1 Cash-Producing Stock on Our Buy List and 2 We Find Risky"
              },
              {
                "id": 142340644,
                "url": "https://finnhub.io/api/news?id=033972e3854745199d16a43e53d2bfecd4f709597d776ba31ba77bbd14999b14",
                "image": "https://image.cnbcfm.com/api/v1/image/108264668-1770841844066-gettyimages-2260574499-DOUSTDAR_INTERVIEW.jpeg?v=1770841930&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.",
                "category": "company",
                "datetime": 1790052809,
                "headline": "Novo defends diversification push as CEO eyes deals beyond obesity"
              },
              {
                "id": 142314895,
                "url": "https://finnhub.io/api/news?id=5623f852d024055cb2d32412012583ba5ea052c3a4adde817ae8a074a9516832",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.",
                "category": "company",
                "datetime": 1790006100,
                "headline": "BMY vs GILD: Which Biotech Stock Looks More Attractive Now?"
              },
              {
                "id": 142311278,
                "url": "https://finnhub.io/api/news?id=002d0b9e4660f8ba700936746f2c2dbab8a6ed55df5a0bceb3491fc5b41eefd6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The drugmaker expects growth in line with industry peers as it works to rebuild its pipeline beyond obesity",
                "category": "company",
                "datetime": 1789993229,
                "headline": "Novo Nordisk Stock Drops 5.6% as 2030 Goals Match Peers"
              },
              {
                "id": 142339172,
                "url": "https://finnhub.io/api/news?id=d51dbd7ada52e4ff52a0b9b92354d8553f2cbbdf9d3c7ec924f0a6c52e5bc1f7",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 4.6% on an annualized basis producing an average annual return of 16.24%. Currently, Gilead Sciences has a market capitalization of",
                "category": "company",
                "datetime": 1789990232,
                "headline": "Here's How Much $1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth Today"
              },
              {
                "id": 142340649,
                "url": "https://finnhub.io/api/news?id=2059a9ef57dbfa8b8e82f89f3b9878fe009b8717089366ff4944c7fa9b32ff70",
                "image": "https://image.cnbcfm.com/api/v1/image/108363158-17894901612026-09-15t163359z_2080430281_rc2qjna3z3zx_rtrmadp_0_novo-nordisk-strategy-townhall.jpeg?v=1789490250&w=1920&h=1080",
                "source": "CNBC",
                "related": "GILD",
                "summary": "The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.",
                "category": "company",
                "datetime": 1789964630,
                "headline": "Novo shares slide as drugmaker lays out post-Wegovy growth strategy"
              },
              {
                "id": 142289621,
                "url": "https://finnhub.io/api/news?id=8847aee5254d1cadb2e440ab092a52ca873646ec53eea5b614b1fffb4f31ad5c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "After sessions with Gilead’s leadership at Morgan Stanley’s 2026 Global Healthcare Conference, the bank reaffirmed its Overweight rating, and one franchise stood out.",
                "category": "company",
                "datetime": 1789920180,
                "headline": "Why Morgan Stanley likes Gilead's HIV prevention play"
              },
              {
                "id": 142277829,
                "url": "https://finnhub.io/api/news?id=7a8453233558d1af67fd7a011617309053c83aa5e2b2f9526c58da60bb2d27d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (NasdaqGS:GILD) expanded its royalty-free voluntary licensing of once-yearly lenacapavir for HIV prevention to 120 high-incidence countries. The biopharma group signed a regional agreement with the Pan American Health Organization to widen access to twice-yearly lenacapavir across Latin America and the Caribbean. The PAHO partnership creates a direct pathway for 14 additional countries in the region to obtain lenacapavir for HIV prevention programs. Gilead's broader licensing...",
                "category": "company",
                "datetime": 1789877873,
                "headline": "Why Is Gilead Sciences (GILD) Widening Lenacapavir Access Across 120 Countries?"
              },
              {
                "id": 142259763,
                "url": "https://finnhub.io/api/news?id=ce01359956cfa697fa14dbec0fa74d52e08052fef60abdd038c3a6770157df4d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) has reached an agreement with the Pan American Health Organization (PAHO) to expand access to its twice-yearly HIV-prevention drug lenacapavir across Latin America and the Caribbean. The agreement creates a regional procurement pathway through PAHO for 14 countries, including Brazil, Mexico, Argentina, Colombia and Peru, that were outside Gilead’s existing voluntary […]",
                "category": "company",
                "datetime": 1789750282,
                "headline": "Gilead Strengthens HIV Growth Platform with Expanded Latin America Access"
              },
              {
                "id": 142258035,
                "url": "https://finnhub.io/api/news?id=2f94d516b9514e3b44250c1ee5b2021449815a5a007c876cadfc15e9a7c16873",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.",
                "category": "company",
                "datetime": 1789749060,
                "headline": "4 Biotech Stocks to Watch as Potential Takeover Targets"
              },
              {
                "id": 142255053,
                "url": "https://finnhub.io/api/news?id=be475871efb7e63509e6725d824caf28cb24c7bebd4aa0cd964870a91f29b1fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.",
                "category": "company",
                "datetime": 1789736700,
                "headline": "J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?"
              },
              {
                "id": 142254787,
                "url": "https://finnhub.io/api/news?id=9e36abb4736760f20f2560d69abeba3d6a402c6a5b6c3ebfc2d1ef95ab93e692",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1630128517/image_1630128517.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Oncology spending may hit $441B by 2029 as growth slows from generics—see 5 underappreciated cancer stocks with catalysts and upside. Click for the picks.",
                "category": "company",
                "datetime": 1789723352,
                "headline": "5 Undervalued Oncology Stocks Wall Street Is Overlooking"
              },
              {
                "id": 142235324,
                "url": "https://finnhub.io/api/news?id=b0d8c0f8c6a725b5bd6f5163684068f5c1476636c095f8b3dcdadec10e95f2b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "MEXICO CITY, September 17, 2026--AIDS Healthcare Foundation (AHF), the world’s largest HIV care provider, welcomes a new agreement between Gilead Sciences and the Pan American Health Organization (PAHO) that could expand access to lenacapavir for HIV prevention in 14 countries across Latin America. The agreement represents a positive step toward expanding access in the region and a victory for civil society.",
                "category": "company",
                "datetime": 1789684560,
                "headline": "Latin America’s PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF"
              },
              {
                "id": 142235325,
                "url": "https://finnhub.io/api/news?id=289ba3334c78c7143d9751ea6bad630a852e94208c3a5c796c6083e9ce09bd63",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.",
                "category": "company",
                "datetime": 1789650004,
                "headline": "Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know"
              },
              {
                "id": 142197169,
                "url": "https://finnhub.io/api/news?id=e75f3b737d90025c607b605e7dfe339e2de02fc4e7e0e1232d8e9e290c3d211b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.",
                "category": "company",
                "datetime": 1789568760,
                "headline": "Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America"
              },
              {
                "id": 142197168,
                "url": "https://finnhub.io/api/news?id=4ded9287680153405d14690cb18989c70c791fc2a8bd7ad575a7949ac7d765c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (NASDAQ:GILD) has expanded six existing royalty-free voluntary licensing agreements to include an investigational once-yearly formulation of lenacapavir for HIV prevention, the company announced. The expanded agreements cover 120 countries with high HIV incidence, primarily low- and lower-middle-income nations.",
                "category": "company",
                "datetime": 1789566407,
                "headline": "Gilead Expands Lenacapavir Licensing Agreements to Include Once-Yearly HIV Prevention Formulation"
              },
              {
                "id": 142195305,
                "url": "https://finnhub.io/api/news?id=dafb6c5da8ed62d8268fa0cc1b15db1e1e09999cd531da589a3f6272e49de310",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif., September 16, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreements cover 120 high-incidence countries (which are primarily low- and lower-middle-income) and will support manufacturing readiness, technology transfer and future supply planning while th",
                "category": "company",
                "datetime": 1789561800,
                "headline": "Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention"
              },
              {
                "id": 142168612,
                "url": "https://finnhub.io/api/news?id=41c20debab4892cfcc8e5df91f607b6ff849d71ca9681a6e3e5467d1f3dd040e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Healthcare stocks were edging lower late Tuesday afternoon, with the NYSE Healthcare Index and the S",
                "category": "company",
                "datetime": 1789501922,
                "headline": "Sector Update: Healthcare Stocks Ease Late Afternoon"
              },
              {
                "id": 142168611,
                "url": "https://finnhub.io/api/news?id=05e03c437e22b4495a6f1a6b9692ef0350d02115e52fd82d5951e2fd56884682",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (NASDAQ:GILD) executives outlined plans to expand the company’s HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief Executive Officer Dan O’Day describing the company as being at an “inflection point in value.” Speaking",
                "category": "company",
                "datetime": 1789495361,
                "headline": "Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances"
              },
              {
                "id": 142165807,
                "url": "https://finnhub.io/api/news?id=5ade9a56eb375da8f28bf3012504f1590b9391ef3d521fba73f42d96f01bcaeb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Healthcare stocks were edging down Tuesday afternoon, with the NYSE Healthcare Index fractionally lo",
                "category": "company",
                "datetime": 1789494294,
                "headline": "Sector Update: Healthcare Stocks Lower Tuesday Afternoon"
              },
              {
                "id": 142165808,
                "url": "https://finnhub.io/api/news?id=aab50ca76bc298dcbddb222504331db4702f2babfb6fb39ac0c29c9ffd5333ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif., September 15, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO Member States in Latin America and the Caribbean. Through PAHO’s Regional Revolving Funds, the agreement establishes a coordinated regional pathway to expand access to long-acting HIV prevention and support country-led eff",
                "category": "company",
                "datetime": 1789485000,
                "headline": "Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean"
              },
              {
                "id": 142164888,
                "url": "https://finnhub.io/api/news?id=b835c9970ebeab2466dae19af131df5eb52315b5528b1066051cc561ce12090e",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (GILD) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 10:45 AM EDTCompany ParticipantsDaniel O'Day -...",
                "category": "company",
                "datetime": 1789477898,
                "headline": "Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
              },
              {
                "id": 142195687,
                "url": "https://finnhub.io/api/news?id=4f7d4f9e26fee45da8f4d0aa3374bb4b5c2eb3ee8b03f594d397b6ef95d5cde8",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "– Agreement Establishes a Regional Pathway Through PAHO’s Regional Revolving Funds to Support Country-Led Adoption of Long-Acting HIV Prevention –– Partnership Advances Gilead’s Global Access Strategy, Helping Turn",
                "category": "company",
                "datetime": 1789470811,
                "headline": "Gilead And PAHO Partner To Expand Twice-Yearly Lenacapavir HIV Prevention Access Across Latin America And The Caribbean"
              },
              {
                "id": 142195688,
                "url": "https://finnhub.io/api/news?id=5559be0d8b3c9cb51da48c2bed670d13dfd8bb31bd9a772baee37d9a8efb3f6e",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "https://event.webcasts.com/starthere.jsp?ei=1776111&tp_key=7239e5582f&tp_special=8",
                "category": "company",
                "datetime": 1789470595,
                "headline": "Gilead Exec Says HIV Market Growth Should Normalize To 2%-3% Within Next Couple Of Quarters"
              },
              {
                "id": 142195689,
                "url": "https://finnhub.io/api/news?id=6147d430c9b60762db277ef84f104128f1335c642705ff6bd63a16b7452fdb0b",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": " - conference call",
                "category": "company",
                "datetime": 1789470383,
                "headline": "Gilead Sciences Exec Says Weekly Oral HIV Prevention Drug Expected To Launch In Q1 2027"
              },
              {
                "id": 142162734,
                "url": "https://finnhub.io/api/news?id=4394075bfdfaa0607d0287d084dfdbfdf4fde8cf81315f0bc3b27c2e7263eb10",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "This article first appeared on GuruFocus.  Gilead Sciences Inc (NASDAQ:GILD) recently announced a total dividend of $0.82 per share, with the ex-dividend date set for 2026-09-15.  This upcoming distribution includes a $0.82 per share cash dividend payable on 2026-09-29.",
                "category": "company",
                "datetime": 1789470075,
                "headline": "Gilead Sciences Inc's Dividend Analysis"
              },
              {
                "id": 142148466,
                "url": "https://finnhub.io/api/news?id=3a55a81182ae3c5e5b4374a25b9a6efef8453c8ec54bf82e452ff204106c0074",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences has delivered a powerful 5 year run in its share price, and fresh headlines around new research facilities and HIV treatments keep attention firmly on its growth story. With the stock now at US$146.42, the live question for investors is whether that market value lines up with what the business is generating in sales. The share price is up 146.6% over 5 years, which puts real pressure on the current sales base to justify where the stock now trades. The new Foster City research...",
                "category": "company",
                "datetime": 1789427954,
                "headline": "Is Gilead Sciences (GILD) Reasonable Given Its Sales Base?"
              },
              {
                "id": 142142918,
                "url": "https://finnhub.io/api/news?id=8a116fdbee1d8eb7ce3ac2da5e876c8b135cc3f4df70260953188f14db7782b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.42, denoting a +1.88% move from the preceding trading day.",
                "category": "company",
                "datetime": 1789423203,
                "headline": "Gilead Sciences (GILD) Gains As Market Dips: What You Should Know"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 79,
            "discarded_article_count": 61
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 19.2,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1,
            "vcp_reason": "跌縮量(近10日5日)；站上MA50；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 5615950,
              "down_days": 6,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 5048770,
              "avg_vol_20": 5829115,
              "avg_vol_30": 5615950,
              "range_pct_10": 0.06740677174810697,
              "range_pct_20": 0.07711221678602778,
              "range_pct_30": 0.07711221678602778,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.899005511088952,
              "dist_to_20d_high": 0.024448832684824808,
              "down_shrink_days": 5,
              "breakout_level_20d": 154.2,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.8741386846023161
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.2435685862905395,
              "turnoverUsdM": 786.90995821929,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.GILD",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 143.68,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 4.5,
            "take_profit_price": 157.9515,
            "target_multiplier": 1.6,
            "technical_strength": 1.38,
            "take_profit_percent": 5
          },
          "positionPoints": 1.6,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.487137172581079,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 3.375,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.24
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "適中偏強",
      "score": 8,
      "value": 61.65
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0479
    },
    "kdj": {
      "d": 45.39,
      "j": 91.47,
      "k": 60.75,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 43.28
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": -1985371,
      "recentSlope": -1454347.1,
      "previousSlope": 103920
    },
    "rsi": 44.71,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 142.7768,
      "position": "SAR喺價下",
      "distancePct": 5.09,
      "previousTrend": "上升"
    },
    "ma50": 145.116,
    "macd": {
      "macd": 0.7106705790379522,
      "trend": "中性偏多",
      "signal": 0.9273034466177024,
      "histogram": -0.2166328675797502
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 6,
      "value": 149.1146,
      "position": "連續1-2日>VWAP",
      "consecutiveAbove": 2
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.9,
      "score": 4,
      "avgVolume": 5844674,
      "currentVolume": 5231071
    },
    "derived": {
      "ma20": 148.9695,
      "ma50": 145.116,
      "prevClose": 151.17,
      "avgVolume10": 5064227,
      "avgVolume20": 5844674,
      "changePercent": -0.49,
      "avgVolumeForScore": 5844674
    },
    "ma_cross": {
      "ma20": 148.9695,
      "ma50": 145.116,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 148.7685,
      "prevMa50": 144.7116,
      "spreadPct": 2.66,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 143.826,
      "upper": 154.113,
      "position": "上半部"
    },
    "rsi_short": 84.74,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.9
    }
  }
}

Raw metrics JSON

 
{
  "close": 150.43,
  "volume": 5231071,
  "changePercent": -0.49
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.